'Nsclc' presentation slideshows

Presentation and management of Lung lesion

Presentation and management of Lung lesion. Supervised by: Dr. Wassim Hajjar. Presented By: Yaser Alshhab Mohammed Alkarzae Sultan Aldrees. Objectives:. To identify lung lesion and how to manage. To differentiate between Benign lung lesions.

1.06k views • 86 slides

Program Goals

Program Goals. Introduction. Using Vaccines in the Treatment of NSCLC. Vaccine Approach in NSCLC Targeting Tumor Antigens. Vaccines Evaluated in Phase 3 Lung Cancer Trials Study Designs. Vaccines Evaluated in Phase 3 Lung Cancer Trials (cont) Study Designs.

715 views • 60 slides

Hurry Up and Wait: The Effect of Delayed Diagnosis and Treatment on Survival in Patients with Non-Small-Cell Lung Canc

Hurry Up and Wait: The Effect of Delayed Diagnosis and Treatment on Survival in Patients with Non-Small-Cell Lung Cancer. Michael K. Gould, MD, MS VA Palo Alto Health Care System Stanford School of Medicine. Lung Cancer. 175,000 new cases in U.S. in 2004 160,000 deaths in U.S. in 2004

898 views • 54 slides

Treatment in Advanced Non-Small Cell Lung Cancer

Treatment in Advanced Non-Small Cell Lung Cancer. NSCLC| Epidemiology- Australia. 5 th most commonly diagnosed cancer in Australia 8.9% of new cancer diagnoses In 2009: 10,193 cases ( 6034 men, 4159 women) Projection to 2020 ? 13,640 Mortality

814 views • 49 slides

Using Non-targeted Therapies in Targeted Lung Cancer Populations

Using Non-targeted Therapies in Targeted Lung Cancer Populations. Nathan Pennell, M.D., Ph.D. September 6, 2014. Objectives. Discuss the role of chemotherapy in molecularly defined populations Discuss the addition of chemo and/or bevacizumab (Avastin) to targeted therapy

647 views • 42 slides

Department of Thoracic Oncology

Filippo de Marinis Department of Thoracic Oncology, IEO, Milan, Italy. Department of Thoracic Oncology. LIFE STUDY 2nd Line TREATMENT. 13%. 52%. 34.0%. C Gridelli, F de Marinis et al, data on file, 2013. ESMO GL WG, Ann Oncol 2012.

619 views • 42 slides

Advanced NSCLC: treatment options for non-squamous, EGFR wildtype tumors

815 views • 41 slides

First-Line Chemotherapy in Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

First-Line Chemotherapy in Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC). Thoracic Tumors. Lung Cancer Globally, 1.4 million new cases each year 1 The leading cause of cancer death worldwide 1 Approximately 80% of lung cancer cases are NSCLC 2 NSCLC

893 views • 39 slides

Targeted Drug Development: Wrong Turns and Blind Alleys On The Road to Success

Targeted Drug Development: Wrong Turns and Blind Alleys On The Road to Success. Janet E. Dancey, MD Investigational Drug Branch Cancer Therapy Evaluation Program National Cancer Institute March 3, 2004.

588 views • 36 slides

Genes and Drugs

Genes and Drugs. OUTLINE . How do we know if a patient will respond to a drug? What are the response rates for different classes of drugs? How are doses determined? Why does drug response vary? Genetic variation What is it? How do you measure it? How extensive is it?

511 views • 35 slides

Targeting ALK in Advanced NSCLC A New Treatment Paradigm

Targeting ALK in Advanced NSCLC A New Treatment Paradigm. Alice T. Shaw, MD PhD Massachusetts General Hospital Cancer Center Harvard Medical School August 25, 2012. Oncogenic Drivers in NSCLC. KRAS 24% 1. EGFR 13% 1. PIK3CA 4% 1. RET ~1% 5. ALK 3% 2. M ET ~1% 4. HER2 2 % 3.

1.24k views • 32 slides

Estimating costs of diagnosis and treatment for lung cancer using linked longitudinal data

406 views • 31 slides

Estimating costs of diagnosis and treatment for lung cancer using linked longitudinal data

396 views • 31 slides

473 views • 26 slides

PARAMOUNT: phase III study of pemetrexed continuation maintenance therapy in advanced non-squamous NSCLC.

PARAMOUNT: phase III study of pemetrexed continuation maintenance therapy in advanced non-squamous NSCLC. All Chapters at a glance: please click on box to review. 1. 2. 3. Maintenance strategies in non-squamous NSCLC. PARAMOUNT: study design and objectives. PARAMOUNT:

641 views • 21 slides

Expediting Drug Development : Breakthrough Therapies

Expediting Drug Development : Breakthrough Therapies. Jeff Allen, PhD Executive Director, Friends of Cancer Research. Courtesy of the American Association of Cancer Research 2011 Cancer Progress Report. The New York Times September 18, 2010 New Drugs Stir Debate on Rules of Clinical Trials

323 views • 13 slides

Lung Cancer

Lung Cancer. Types, Causes, Symptoms, Treatments, Statistics, & pictures Heather XXXXXXX , 1 st Period. http://www.topnews.in/health/study-proposes-new-treatments-lung-disease-patients-2980. Types of Lung Cancer.

351 views • 11 slides

Patients who received PORT were younger than patients who did not receive PORT.

Postoperative Radiotherapy for Patients with Stage II or III Nonsmall Cell Lung Cancer treated with Sublobar Resections: A SEER Registry Analysis

169 views • 4 slides

Supplementary Figure S1

Supplementary Figure S1. BEX family. NXF family. TCEAL family.

101 views • 1 slides

Caner specimens

Functional screening of transforming genes. Caner specimens. Retroviral cDNA expression library. Discovery of the first fusion-type oncogene, EML4-ALK, in non-small cell lung cancer (NSCLC). ( Nature 448:561, 2007).

142 views • 1 slides